Industry Bulletins | September 2, 2018
FDA Approves Brain Stimulation Device For Obsessive-Compulsive Disorder
The U.S. Food and Drug Administration (FDA) recently approved a brain stimulation device for the treatment of obsessive-compulsive disorder (OCD). The treatment, transcranial magnetic stimulation (TMS), uses magnetic fields to stimulate nerve cells in the brain, and was previously approved in 2008 and 2013 for the treatment of major depression and migraine pain, respectively.
The new treatment option is expected to particularly benefit individuals with OCD who have not responded positively to more traditional OCD treatments, providing them with a new choice for symptom relief. The approval for the treatment comes from a study utilizing BrainsWay’s Deep . . .